Follicular lymphoma international prognostic index

Philippe Solal-Céligny, Pascal Roy, Philippe Colombat, Josephine White, Jim O. Armitage, Reyes Arranz-Saez, Wing Y. Au, Monica Bellei, Pauline Brice, Dolores Caballero, Bertrand Coiffier, Eulogio Conde-Garcia, Chantal Doyen, Massimo Federico, Richard I. Fisher, Javier F. Garcia-Conde, Cesare Guglielmi, Anton Hagenbeek, Corinne Haïoun, Michael LeBlancAndrew T. Lister, Armando Lopez-Guillermo, Peter McLaughlin, Noël Milpied, Pierre Morel, Nicolas Mounier, Stephen J. Proctor, Ama Rohatiner, Paul Smith, Pierre Soubeyran, Hervé Tilly, Umberto Vitolo, Pier Luigi Zinzani, Emanuele Zucca, Emili Montserrat

Research output: Contribution to journalArticle

1149 Citations (Scopus)

Abstract

The prognosis of follicular lymphomas (FL) is heterogeneous and numerous treatments may be proposed. A validated prognostic index (PI) would help In evaluating and choosing these treatments. Characteristics at diagnosis were collected from 4167 patients with FL diagnosed between 1985 and 1992. Univariate and multivariate analyses were used to propose a PI. This index was then tested on 919 patients. Five adverse prognostic factors were selected: age (> 60 years vs ≤ 60 years), Ann Arbor stage (III-IV vs I-II), hemoglobin level (< 120 g/L vs ≥ 120 g/L), number of nodal areas (> 4 vs ≥ 4), and serum LDH level (above normal vs normal or below). Three risk groups were defined: low risk (0-1 adverse factor, 36% of patients), intermediate risk (2 factors, 37% of patients, hazard ratio [HR] of 2.3), and poor risk (≥ 3 adverse factors, 27% of patients, HR = 4.3). This Follicular Lymphoma International Prognostic Index (FLIPI) appeared more discriminant than the International Prognostic Index proposed for aggressive non-Hodgkin lymphomas. Results were very similar in the confirmation group. The FLIPI may be used for improving treatment choices, comparing clinical trials, and designing studies to evaluate new treatments.

Original languageEnglish (US)
Pages (from-to)1258-1265
Number of pages8
JournalBlood
Volume104
Issue number5
DOIs
StatePublished - Sep 1 2004

Fingerprint

Follicular Lymphoma
Hazards
Therapeutics
Hemoglobins
Non-Hodgkin's Lymphoma
Multivariate Analysis
Clinical Trials
Serum

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Solal-Céligny, P., Roy, P., Colombat, P., White, J., Armitage, J. O., Arranz-Saez, R., ... Montserrat, E. (2004). Follicular lymphoma international prognostic index. Blood, 104(5), 1258-1265. https://doi.org/10.1182/blood-2003-12-4434

Follicular lymphoma international prognostic index. / Solal-Céligny, Philippe; Roy, Pascal; Colombat, Philippe; White, Josephine; Armitage, Jim O.; Arranz-Saez, Reyes; Au, Wing Y.; Bellei, Monica; Brice, Pauline; Caballero, Dolores; Coiffier, Bertrand; Conde-Garcia, Eulogio; Doyen, Chantal; Federico, Massimo; Fisher, Richard I.; Garcia-Conde, Javier F.; Guglielmi, Cesare; Hagenbeek, Anton; Haïoun, Corinne; LeBlanc, Michael; Lister, Andrew T.; Lopez-Guillermo, Armando; McLaughlin, Peter; Milpied, Noël; Morel, Pierre; Mounier, Nicolas; Proctor, Stephen J.; Rohatiner, Ama; Smith, Paul; Soubeyran, Pierre; Tilly, Hervé; Vitolo, Umberto; Zinzani, Pier Luigi; Zucca, Emanuele; Montserrat, Emili.

In: Blood, Vol. 104, No. 5, 01.09.2004, p. 1258-1265.

Research output: Contribution to journalArticle

Solal-Céligny, P, Roy, P, Colombat, P, White, J, Armitage, JO, Arranz-Saez, R, Au, WY, Bellei, M, Brice, P, Caballero, D, Coiffier, B, Conde-Garcia, E, Doyen, C, Federico, M, Fisher, RI, Garcia-Conde, JF, Guglielmi, C, Hagenbeek, A, Haïoun, C, LeBlanc, M, Lister, AT, Lopez-Guillermo, A, McLaughlin, P, Milpied, N, Morel, P, Mounier, N, Proctor, SJ, Rohatiner, A, Smith, P, Soubeyran, P, Tilly, H, Vitolo, U, Zinzani, PL, Zucca, E & Montserrat, E 2004, 'Follicular lymphoma international prognostic index', Blood, vol. 104, no. 5, pp. 1258-1265. https://doi.org/10.1182/blood-2003-12-4434
Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R et al. Follicular lymphoma international prognostic index. Blood. 2004 Sep 1;104(5):1258-1265. https://doi.org/10.1182/blood-2003-12-4434
Solal-Céligny, Philippe ; Roy, Pascal ; Colombat, Philippe ; White, Josephine ; Armitage, Jim O. ; Arranz-Saez, Reyes ; Au, Wing Y. ; Bellei, Monica ; Brice, Pauline ; Caballero, Dolores ; Coiffier, Bertrand ; Conde-Garcia, Eulogio ; Doyen, Chantal ; Federico, Massimo ; Fisher, Richard I. ; Garcia-Conde, Javier F. ; Guglielmi, Cesare ; Hagenbeek, Anton ; Haïoun, Corinne ; LeBlanc, Michael ; Lister, Andrew T. ; Lopez-Guillermo, Armando ; McLaughlin, Peter ; Milpied, Noël ; Morel, Pierre ; Mounier, Nicolas ; Proctor, Stephen J. ; Rohatiner, Ama ; Smith, Paul ; Soubeyran, Pierre ; Tilly, Hervé ; Vitolo, Umberto ; Zinzani, Pier Luigi ; Zucca, Emanuele ; Montserrat, Emili. / Follicular lymphoma international prognostic index. In: Blood. 2004 ; Vol. 104, No. 5. pp. 1258-1265.
@article{92ba358e0aa14dc289c0208bccdacc2e,
title = "Follicular lymphoma international prognostic index",
abstract = "The prognosis of follicular lymphomas (FL) is heterogeneous and numerous treatments may be proposed. A validated prognostic index (PI) would help In evaluating and choosing these treatments. Characteristics at diagnosis were collected from 4167 patients with FL diagnosed between 1985 and 1992. Univariate and multivariate analyses were used to propose a PI. This index was then tested on 919 patients. Five adverse prognostic factors were selected: age (> 60 years vs ≤ 60 years), Ann Arbor stage (III-IV vs I-II), hemoglobin level (< 120 g/L vs ≥ 120 g/L), number of nodal areas (> 4 vs ≥ 4), and serum LDH level (above normal vs normal or below). Three risk groups were defined: low risk (0-1 adverse factor, 36{\%} of patients), intermediate risk (2 factors, 37{\%} of patients, hazard ratio [HR] of 2.3), and poor risk (≥ 3 adverse factors, 27{\%} of patients, HR = 4.3). This Follicular Lymphoma International Prognostic Index (FLIPI) appeared more discriminant than the International Prognostic Index proposed for aggressive non-Hodgkin lymphomas. Results were very similar in the confirmation group. The FLIPI may be used for improving treatment choices, comparing clinical trials, and designing studies to evaluate new treatments.",
author = "Philippe Solal-C{\'e}ligny and Pascal Roy and Philippe Colombat and Josephine White and Armitage, {Jim O.} and Reyes Arranz-Saez and Au, {Wing Y.} and Monica Bellei and Pauline Brice and Dolores Caballero and Bertrand Coiffier and Eulogio Conde-Garcia and Chantal Doyen and Massimo Federico and Fisher, {Richard I.} and Garcia-Conde, {Javier F.} and Cesare Guglielmi and Anton Hagenbeek and Corinne Ha{\"i}oun and Michael LeBlanc and Lister, {Andrew T.} and Armando Lopez-Guillermo and Peter McLaughlin and No{\"e}l Milpied and Pierre Morel and Nicolas Mounier and Proctor, {Stephen J.} and Ama Rohatiner and Paul Smith and Pierre Soubeyran and Herv{\'e} Tilly and Umberto Vitolo and Zinzani, {Pier Luigi} and Emanuele Zucca and Emili Montserrat",
year = "2004",
month = "9",
day = "1",
doi = "10.1182/blood-2003-12-4434",
language = "English (US)",
volume = "104",
pages = "1258--1265",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Follicular lymphoma international prognostic index

AU - Solal-Céligny, Philippe

AU - Roy, Pascal

AU - Colombat, Philippe

AU - White, Josephine

AU - Armitage, Jim O.

AU - Arranz-Saez, Reyes

AU - Au, Wing Y.

AU - Bellei, Monica

AU - Brice, Pauline

AU - Caballero, Dolores

AU - Coiffier, Bertrand

AU - Conde-Garcia, Eulogio

AU - Doyen, Chantal

AU - Federico, Massimo

AU - Fisher, Richard I.

AU - Garcia-Conde, Javier F.

AU - Guglielmi, Cesare

AU - Hagenbeek, Anton

AU - Haïoun, Corinne

AU - LeBlanc, Michael

AU - Lister, Andrew T.

AU - Lopez-Guillermo, Armando

AU - McLaughlin, Peter

AU - Milpied, Noël

AU - Morel, Pierre

AU - Mounier, Nicolas

AU - Proctor, Stephen J.

AU - Rohatiner, Ama

AU - Smith, Paul

AU - Soubeyran, Pierre

AU - Tilly, Hervé

AU - Vitolo, Umberto

AU - Zinzani, Pier Luigi

AU - Zucca, Emanuele

AU - Montserrat, Emili

PY - 2004/9/1

Y1 - 2004/9/1

N2 - The prognosis of follicular lymphomas (FL) is heterogeneous and numerous treatments may be proposed. A validated prognostic index (PI) would help In evaluating and choosing these treatments. Characteristics at diagnosis were collected from 4167 patients with FL diagnosed between 1985 and 1992. Univariate and multivariate analyses were used to propose a PI. This index was then tested on 919 patients. Five adverse prognostic factors were selected: age (> 60 years vs ≤ 60 years), Ann Arbor stage (III-IV vs I-II), hemoglobin level (< 120 g/L vs ≥ 120 g/L), number of nodal areas (> 4 vs ≥ 4), and serum LDH level (above normal vs normal or below). Three risk groups were defined: low risk (0-1 adverse factor, 36% of patients), intermediate risk (2 factors, 37% of patients, hazard ratio [HR] of 2.3), and poor risk (≥ 3 adverse factors, 27% of patients, HR = 4.3). This Follicular Lymphoma International Prognostic Index (FLIPI) appeared more discriminant than the International Prognostic Index proposed for aggressive non-Hodgkin lymphomas. Results were very similar in the confirmation group. The FLIPI may be used for improving treatment choices, comparing clinical trials, and designing studies to evaluate new treatments.

AB - The prognosis of follicular lymphomas (FL) is heterogeneous and numerous treatments may be proposed. A validated prognostic index (PI) would help In evaluating and choosing these treatments. Characteristics at diagnosis were collected from 4167 patients with FL diagnosed between 1985 and 1992. Univariate and multivariate analyses were used to propose a PI. This index was then tested on 919 patients. Five adverse prognostic factors were selected: age (> 60 years vs ≤ 60 years), Ann Arbor stage (III-IV vs I-II), hemoglobin level (< 120 g/L vs ≥ 120 g/L), number of nodal areas (> 4 vs ≥ 4), and serum LDH level (above normal vs normal or below). Three risk groups were defined: low risk (0-1 adverse factor, 36% of patients), intermediate risk (2 factors, 37% of patients, hazard ratio [HR] of 2.3), and poor risk (≥ 3 adverse factors, 27% of patients, HR = 4.3). This Follicular Lymphoma International Prognostic Index (FLIPI) appeared more discriminant than the International Prognostic Index proposed for aggressive non-Hodgkin lymphomas. Results were very similar in the confirmation group. The FLIPI may be used for improving treatment choices, comparing clinical trials, and designing studies to evaluate new treatments.

UR - http://www.scopus.com/inward/record.url?scp=4444326818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444326818&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-12-4434

DO - 10.1182/blood-2003-12-4434

M3 - Article

C2 - 15126323

AN - SCOPUS:4444326818

VL - 104

SP - 1258

EP - 1265

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -